CorVel Corporation (CRVL) - Q2 2025 (Fiscal) Summary
Business Context and Reporting Period
This summary covers CorVel Corporation's Form 10-Q for the quarterly period ended September 30, 2024 (Fiscal Q2 2025). CorVel is an independent nationwide provider of medical cost containment and managed care services, primarily serving workers' compensation, automobile insurance, and group health insurance payors. The company operates in a single reportable segment: Managed Care.
Key Financial Metrics
| Metric | Q2 2024 (Current) | Q2 2023 (Prior Year) | 6 Months 2024 (YTD) | 6 Months 2023 (YTD) |
|---|---|---|---|---|
| Revenues | $224.4 million | $195.5 million | $436.1 million | $385.8 million |
| Net Income | $23.4 million | $19.9 million | $45.0 million | $39.7 million |
| Diluted EPS | $1.35 | $1.15 | $2.60 | $2.29 |
| Gross Margin | 22.6% | 22.6% | 22.7% | 22.3% |
| Cash & Equivalents | $138.3 million | $91.7 million (Sep 2023) | Balance Sheet as of Sep 30, 2024 | |
| Working Capital | $150.5 million | $117.7 million (Mar 2024) | ||
| Operating Cash Flow (6mo) | $62.7 million | $54.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14.8% year-over-year for the quarter and 13.0% for the six-month period. This growth was driven by increased activity in both Patient Management (up 13.4% QoQ) and Network Solutions (up 17.5% QoQ).
- Profitability: Net income rose 17.6% for the quarter and 13.3% for the six-month period. Diluted EPS increased 17.4% for the quarter.
- Expense Management: Cost of revenues increased 14.8%, tracking closely with revenue growth. General and administrative (G&A) expenses increased 13.0% for the quarter, remaining at approximately 10% of revenues.
- Liquidity: Cash and cash equivalents increased by $32.8 million compared to the prior fiscal year-end (March 31, 2024), driven by strong operating cash flows and reduced share repurchase spending.
Outlook, Risks, and Management Commentary
- Guidance: Management expects G&A expenses to remain between 9% and 11% of revenues in future quarters. No specific forward-looking revenue guidance was provided in this filing.
- Capital Allocation: The company continues its stock repurchase program. During the quarter, it repurchased 32,123 shares for $9.6 million. As of September 30, 2024, 896,560 shares remained available under the program.
- Risk Factors: Key risks include declining workers' compensation claims due to fewer workplace injuries, increased competition, inflationary pressures on labor and benefits, and potential regulatory changes in healthcare and workers' compensation laws. Cybersecurity risks and the ability to retain key personnel are also highlighted.
- Unusual Items: The prior year's G&A expenses were favorably impacted by a one-time insurance recovery settlement in the second quarter of fiscal 2024, which contributed to the year-over-year expense increase.
Investor Verification Checklist
- Claim Volume Trends: Verify the sustainability of the 5% increase in total new claims reported for the quarter against broader industry injury statistics.
- Customer Concentration: Review the top 10 customers list (if available in the full 10-K) to assess dependency risks, as the company notes that losing several customers could materially impact results.
- Stock Repurchase Pace: Monitor the remaining authorization under the buyback program ($896,560 shares) and the average price paid ($298.49/share) relative to current market prices.
- Regulatory Environment: Track state-level legislative changes regarding workers' compensation and managed care licensing that could affect service demand or pricing.
- Deferred Revenue: Note the $29.96 million in deferred revenue (contract liabilities) and the expectation that 98% will be recognized within one year.